Table 1.
Therapies that can induce arrythmias.
| Chemotherapeutic Agent | Risk for Arrythmia | |
|---|---|---|
| ALK inhibitors * | Doxorubicin | high risk |
| Epirubicin | high risk | |
| Idarubicin | high risk | |
| Mitoxantrone | high risk | |
| Alkylating agents | Busulfan | high risk |
| Cyclophosphamide A | low risk | |
| Ifosfamide | no risk | |
| Melphalan | medium risk | |
| CDK4/CDK6 inhibitors ** | Ribociclib | medium risk |
| Immune checkpoint inhibitors | Ipilimumab (anti-CTLA4) | low risk |
| Nivolumab (anti-PD1) | low risk | |
| Pembrolizumab (anti-PD1) | low risk | |
| Microtubule-binding agents | Docetaxel | medium risk |
| Paclitaxel | low risk | |
| Vinblastine | no risk | |
| Vincristine | no risk |
* ALK (anaplastic lymphoma kinase) inhibitors; ** CDK4/CDK6 (cyclin-dependent kinase 4 and 6) inhibitors.